Citius Oncology Inc Dossier
Qualitative Analysis
Business overview
Citius Oncology, Inc. (Nasdaq: CTOR) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The company operates as a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), which holds an approximate 71.0% controlling interest. Citius Oncology's lead FDA-approved product is LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved by the FDA in August 2024 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. The company acquired the exclusive license to develop and commercialize LYMPHIR in all global markets (excluding Japan, China, and certain other parts of Asia) through agreements with Eisai Co., Ltd. and Dr. Reddy's Laboratories.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing a highly targeted commercial launch of LYMPHIR in the U.S. by establishing distribution agreements with major wholesalers (Cardinal Health, Cencora, McKesson) and securing formulary inclusion.
Expected impact: Targeting an addressable U.S. CTCL market estimated to exceed $400 million.
Partnering with regional distribution networks to make LYMPHIR available to eligible patients outside the U.S. through Named Patient Programs (NPPs) in Europe, South America, and the Middle East.
Expected impact: Establishes early international market presence and provides access to patients in regions without formal marketing authorization.
Supporting investigator-initiated trials to evaluate LYMPHIR's potential as a combination therapy with checkpoint inhibitors (e.g., pembrolizumab) to deplete regulatory T-cells (Tregs) and enhance anti-tumor immunity.
Expected impact: Expands the therapeutic utility of LYMPHIR into solid tumors and other hematologic malignancies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Citius Oncology with exclusive development and commercialization rights to LYMPHIR in all markets except Japan and certain parts of Asia.
Terms: Includes milestone payments upon FDA approval and additional commercial milestones based on net product sales thresholds, alongside cost reimbursements for clinical trials.
Acquisition of rights and intellectual property related to the development and commercialization of LYMPHIR.
Terms: Involves milestone payment obligations totaling over $22 million shared between Eisai and Dr. Reddy's.
Provides non-dilutive debt capital to fund the commercial launch and scale-up of LYMPHIR.
Terms: Senior secured term loan facility providing up to $25 million in capital bearing an interest rate of at least 12.75%.